No Data
No Data
Outlook Therapeutics Issues Convertible Note to Avondale
Outlook Therapeutics Files to Sell 7.07M Shares of Common Stock for Holders
Outlook Therapeutics Shares Are Trading Higher After the Company Re-submitted Its Biologics License Application for ONS-5010 in Wet AMD to the FDA.
Outlook Therapeutics Re-Submits Its Biologics License Application For ONS-5010 In Wet AMD To The FDA
Express News | Outlook Therapeutics Inc - FDA Decision Expected Within Six Months
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration